Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 148,301 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 148,301 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $64.76, for a total value of $9,603,972.76. Following the completion of the transaction, the director owned 1,636,941 shares in the company, valued at $106,008,299.16. The trade was a 8.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $65.25 on Thursday. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $66.78. The stock’s 50 day moving average price is $48.50 and its 200-day moving average price is $40.37. The company has a market capitalization of $5.80 billion, a PE ratio of 466.10 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. The business’s revenue was up 4187.1% compared to the same quarter last year. On average, equities analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LQDA. Wall Street Zen upgraded Liquidia from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Wells Fargo & Company upped their price objective on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research note on Thursday, June 4th. Finally, Needham & Company LLC upped their price objective on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.29.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. bought a new position in shares of Liquidia in the fourth quarter worth $25,000. NewEdge Advisors LLC bought a new position in shares of Liquidia in the second quarter worth $25,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Liquidia in the third quarter worth $30,000. FNY Investment Advisers LLC bought a new position in shares of Liquidia in the third quarter worth $34,000. Finally, Covestor Ltd increased its holdings in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).